Novel therapeutic approaches for T2DM and obesity treatment rely on the incretin effect of GLP-1R agonists on both pancreatic β-cells and other peripheral and central mechanisms of action. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.